Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

PharmacoEconomics - 1 Oct 2013

Blázquez-Pérez Antonio, San Miguel Ramón, Mar Javier

Abstract excerpt

BACKGROUND: Chronic hepatitis C is the leading cause of chronic liver disease, representing a significant burden in terms of morbidity, mortality and costs. A new scenario of therapy for hepatitis C virus (HCV) genotype 1 infection is being established with the approval of two effective HCV protease inhibitors (PIs) in combination with the standard of care (SOC), peginterferon and ribavirin. OBJECTIVE: Our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Interferon alpha-2
Share to Interleukins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Markov Chains

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Protease Inhibitors

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 24000086
DOI: 10.1007/s40273-013-0080-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.PMID 24000086Read ↗

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C.Semantic proximity Read ↗

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.Semantic proximity Read ↗

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.Semantic proximity Read ↗

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.Semantic proximity Read ↗

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.Semantic proximity Read ↗

Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.